PACB Pacific Biosciences of California Inc.

PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025

PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025

MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2024 financial results on Thursday, February 13, 2025, at 4:30 pm Eastern Time.

The call will be webcast and may be accessed at PacBio’s website at .

Date: Thursday, February 13, 2025, at 4:30 pm ET (1:30 pm PT)

Listen live via internet or replay:

Toll-free: 1-888-349-0136

International: 1-412-317-0459

If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the “PacBio Q4 Earnings Call.”

About PacBio

Pacific Biosciences of California, Inc. (NASDAQ: PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clinical researchers resolve genetically complex problems. Our products and technologies stem from two highly differentiated core technologies focused on accuracy, quality, and completeness, which include our HiFi long-read sequencing and our SBB® short-read sequencing technologies. Our products address solutions across a broad set of research applications, including human germline sequencing, plant and animal sciences, infectious disease and microbiology, oncology, and other emerging applications. For more information, please visit and follow @PacBio.

PacBio products are provided for Research Use Only. Not for use in diagnostic procedures.

Contacts

Investors:

Todd Friedman

Media:



EN
30/01/2025

Underlying

PACBPacific Biosciences of California Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Pacific Biosciences of California Inc.

 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio Board Independent Investigation Concludes Allegations Unsubstan...

PacBio Board Independent Investigation Concludes Allegations Unsubstantiated MENLO PARK, Calif., May 12, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced that the Special Committee of its Board of Directors (the “Special Committee”) has concluded its independent investigation into previously disclosed allegations from an attorney representing an employee impacted by our recent reduction in force regarding certain employment practices and cybersecurity matters of the Company. The allegations did not involve the current, or any previously reported, financial results, and the i...

May 12, 2025 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio Announces First Quarter 2025 Financial Results

PacBio Announces First Quarter 2025 Financial Results MENLO PARK, Calif., May 08, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2025. First quarter results:  Q1 2025Q1 2024Revenue$37.2 million$38.8 millionInstrument revenue$11.0 million$19.0 millionConsumable revenue$20.1 million$16.0 millionService and other revenue$6.0 million$3.8 millionRevio™ systems1228Vega™ systems28—Annualized Revio pull-through per system~$236,000~$254,000Cash, cash equivalents, and investments$343.1 million$561.9 million Gross margin, operating e...

May 8, 2025 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newbo...

First Effort to Integrate PacBio HiFi Whole Genome Sequencing in Newborn Screening Launches in Thailand Collaboration leverages HiFi’s unique ability to reveal hidden variants, bringing a new level of precision to early life genetic screening MENLO PARK, Calif. and BANGKOK, May 05, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB) a leading provider of high-quality, highly accurate sequencing platforms, and Chulalongkorn University, a national leader in genomic and translational research, today announced a strategic collaboration to implement PacBio HiFi whole genome sequencing (WGS) as pa...

May 5, 2025 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

PacBio Announces Plans to Improve Methylation Detection in HiFi Chemis...

PacBio Announces Plans to Improve Methylation Detection in HiFi Chemistry Company licenses novel deep learning-based epigenetic models from CUHK enabling the detection of 5hmC, 5mC hemimethylation, and 6mA in standard sequencing runs MENLO PARK, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- PacBio (Nasdaq: PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced it plans to improve on its already highly accurate methylation detection capabilities in HiFi chemistry through licensing advanced DNA methylation detection methods developed by Professor Den...

April 28, 2025 1 EN
 PRESS RELEASE
Free
PACB Pacific Bioscie...

Davos Alzheimer’s Collaborative Selects PacBio as Technology Partner f...

Davos Alzheimer’s Collaborative Selects PacBio as Technology Partner for Global Project to Advance Alzheimer’s Disease Research in North Africa International research team aims to develop better understanding of Alzheimer’s disease and dementia in diverse populations MENLO PARK, Calif. and GENEVA, Switzerland , April 22, 2025 (GLOBE NEWSWIRE) -- The Davos Alzheimer’s Collaborative (DAC), a global initiative to prevent Alzheimer’s disease and improve brain health, today announced that PacBio (NASDAQ: PACB), a leader in high-quality, highly-accurate long-read sequencing platforms, will be...

April 22, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch